ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myotonic Dystrophy 1
Conditions
Myotonic Dystrophy 1
Trial Timeline
Mar 4, 2024 → Dec 1, 2026
NCT ID
NCT06138743About ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection is a phase 1/2 stage product being developed by Arrowhead Pharmaceuticals for Myotonic Dystrophy 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06138743. Target conditions include Myotonic Dystrophy 1.
What happened to similar drugs?
0 of 2 similar drugs in Myotonic Dystrophy 1 were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06138743 | Phase 1/2 | Recruiting |
Competing Products
16 competing products in Myotonic Dystrophy 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 20 |
| Tideglusib | AMO Pharma | Phase 2 | 25 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 28 |
| Tideglusib | AMO Pharma | Phase 2/3 | 35 |
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 39 |
| SAR446268 | Sanofi | Phase 1/2 | 39 |
| rhIGF-I/rhIGFBP-3 + placebo | Insmed | Phase 2 | 32 |
| IONIS-DMPKRx + Placebo | Ionis Pharmaceuticals | Phase 1/2 | 29 |
| Del-desiran (AOC 1001) | Avidity Biosciences | Phase 3 | 44 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 41 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 33 |
| Pitolisant Oral Tablet + Placebo oral tablet | Harmony Biosciences | Phase 2 | 29 |
| PGN-EDODM1 | PepGen | Phase 2 | 32 |
| PGN-EDODM1 | PepGen | Phase 2 | 32 |
| PGN-EDODM1 for infusion | PepGen | Phase 1 | 19 |